Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

被引：6

作者：

Richardson, Paul G. ^{[1
]}

Sandhu, Irwindeep ^{[2
]}

Hofmeister, Craig C. ^{[3
]}

Orlowski, Robert Z. ^{[4
]}

White, Darrell ^{[5
,6
]}

Belotti, Angelo ^{[7
]}

Hansen, Charlotte Toftmann ^{[8
]}

Raje, Noopur S. ^{[9
]}

Chow, Tracy T. ^{[10
]}

Zhou, Zehua ^{[10
]}

Civardi, Tiziana ^{[11
]}

Koo, Phillip ^{[10
]}

Zhu, Yue ^{[10
]}

Katz, Jessica ^{[10
]}

Oriol, Albert ^{[12
,13
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Cross Canc Inst, Edmonton, AB, Canada

[3] Winship Canc Inst Emory Univ, Atlanta, GA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[7] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[8] Odense Univ Hosp, Odense, Denmark

[9] Massachusetts Gen Hosp, Boston, MA USA

[10] Bristol Myers Squibb, Princeton, NJ USA

[11] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

[12] Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain

[13] Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174443

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Talquetamab plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results
Dholaria, Bhagirathbhai
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Harmut
Martin, Thomas
Morillo, Daniel
Reece, Donna
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, M. Damiette
Wasch, Ralph
van de Donk, Niels
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S476 - S477
[42] Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1-3 prior therapies: phase 2 study interim analysis (IA)
Orlowski, Robert
Delimpasi, Sosana
Straub, Jan
Symeonidis, Argiris
Pour, Ludek
Hajek, Roman
Touzeau, Cyrille
Bhanderi, Viralkumar
Pavlicek, Petr
Robak, Pawel
Berdeja, Jesus G.
Matous, Jeffrey V.
Karlin, Lionel
Zweegman, Sonja
Grosicki, Sebastian
Pluta, Andrzej
Kambhampati, Suman
Suryanarayan, Kaveri
Twumasi-Ankrah, Philip
Dash, Ajeeta
Labotka, Richard
Dimopoulos, Meletios-Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S155
[43] Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
Palumbo, A.
Offidani, M.
Pegourie, B.
De La Rubia, J.
Garderet, L.
Laribi, K.
Bosi, A.
Marasca, R.
Laubach, J.
Mohrbacher, A.
Carella, A. M.
Singhal, A. K.
Lynch, M.
Jou, Y-M
Jakubowiak, A.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 28 - 28
[44] Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)
Qian, Xiaozhong
Newhall, Kathryn
Tometsko, Mark
Bjorklund, Chad
Ma, Jianglin
Bahlis, Nizar J.
Siegel, David
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin W.
Seet, Christopher S.
Talamo, Giampaolo
Srinivas, Shanthi
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Mouro, Jorge
Agarwal, Amit
Zafar, Faiza
Thakurta, Anjan
BLOOD, 2017, 130
[45] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations
Nadeem, Omar
Richardson, Paul G.
Mateos, Maria-Victoria
Oriol, Albert
Larocca, Alessandra
Creixenti, Joan Blade
Rodriguez-Otero, Paula
Leleu, Xavier
Norkin, Maxim
Hiemenz, John W.
Hassoun, Hani
Touzeau, Cyrille
Amor, Adrian Alegre
Paner, Agne
Maisel, Christopher
Mazumder, Amitabha
Raptis, Anastasios
Puig, Noemi
Sandberg, Anna
Pelaez, Ivonne
Jaques, Christian
Orre, Marie
Cavo, Michele
BLOOD, 2020, 136
[46] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Schlossman, R.
Munshi, N.
Knight, R.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[47] Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
Mateos, Maria-Victoria
Richardson, Paul
Weisel, Katja
Moreau, Philippe
San-Miguel, Jesus
Goldschmidt, Hartmut
Orlowski, Robert
Sonneveld, Pieter
Reece, Donna E.
Suzuki, Kenshi
Bahlis, Nizar
Yoon, Sung-Soo
Spencer, Andrew
Nooka, Ajay
Hungria, Vania
Plesner, Torben
Ben Yehuda, Dina
Pei, Huiling
Mayo, Wendy Garvin
Gai, Xue
Carey, Jodi
Carson, Robin
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S179 - S180
[48] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study
van de Donk, Niels W. C. J.
Popat, Rakesh
Larsen, Jeremy
Minnema, Monique C.
Jagannath, Sundar
Oriol, Albert
Zonder, Jeffrey A.
Richardson, Paul G.
Rodriguez Otero, Paula
Badros, Ashraf Z.
Stadtmauer, Edward
Bringhen, Sara
Campagnaro, Erica
Siegel, David S.
Gamberi, Barbara
Gironella Mesa, Mercedes
Sonneveld, Pieter
Tuong Vi Nguyen
Di Micco, Antonia
Sorrell, April
Chen, Min
Amatangelo, Michael
Kueenburg, Elisabeth
Lonial, Sagar
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 17 - 18
[49] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Mikhael, Joseph
Richardson, Paul G.
Usmani, Saad Zafar
Raje, Noopur S.
Bensinger, William
Dubin, Franck
Liu, Qianying
Vitse, Olivier
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[50] ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Up-dated Efficacy and Safety
Ocio, Enrique M.
Efebera, Yvonne A.
Hajek, Roman
Granell, Miquel
Maisnar, Vladimir
Straub, Jan
Eveillard, Jean-Richard
Karlin, Lionel
Ribrag, Vincent
Mateos, Maria-Victoria
Oriol, Albert
Sydvander, Malin
Norin, Stefan
Mannikko, Sofia
Pour, Ludek
BLOOD, 2020, 136

← 1 2 3 4 5 →